CASE STUDY | SAFETY AND EFFECTIVENESS MATTER
SAFETY AND EFFECTIVENESS MATTER
Client Success Story
The Situation
- An ultra-rare, fatal childhood condition exists with no effective treatment
- Condition affects 36 infants per year in the U.S.
The Solution
- Regulatory and Quality Consulting consultants submit an Orphan Drug and Pre-IND/End of Phase 2 (EOP2) Briefing Document to FDA
- Secure meeting with the FDA
The Results
- FDA approves small clinical trial (25 patients)
- Orphan Designation granted
- Improved chances of therapy development
FDA approves small clinical trial (25 patients)
Orphan Designation granted
Improved chances of therapy development
Results Matter.
Ask us how we can help you commercialize orphan therapies.